ALLO (ALLO) Stock Analysis
Verdict: AVOID
Clinical-stage CAR-T pipeline potential is eclipsed by $150M annual cash burn and continuous equity dilution before 2029 revenue scaling.
Investment score: 39/100
Is ALLO Stock Worth Reviewing? AI Model Thesis
The AI model recommends an AVOID stance on Allogene Therapeutics (ALLO). While the company's off-the-shelf CAR-T pipeline offers potential long-term optionality, annual cash burn of ~$150M creates severe dilution risk for shareholders before revenue meaningfully scales toward consensus targets in 2028-2029.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| AURA | -3.38 | 1.81 | 0.00 | -4.34 | — | 0.00 |
| ALT | -4.09 | 1.25 | 20012.00 | -6.40 | — | -2960.00 |
| NGNE | -5.61 | 3.21 | 0.00 | -3.62 | — | 0.00 |
| MNPR | -38.20 | 5.83 | 0.00 | -29.52 | — | 0.00 |
| CTMX | -6.18 | 2.01 | 33.07 | -7.59 | — | -4.35 |
Should You Buy or Sell ALLO Stock? Model Reasoning
The model sees severe cash burn (-$149.63M FCF in 2025) and consistent insider selling (15 sells vs 0 buys) outweighing consensus analyst optimism. With no significant commercial revenue expected until 2028-2029 ($80M projected in 2028), the stock faces ongoing dilution risk that penalizes valuation.
ALLO Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Annual FCF burn stabilizes near -$150M without accelerating R&D expenditures","Total current assets of $257.7M provide ~20 months of operational runway into late 2027 before major dilutive financing","Consensus revenue targets of $10M in 2027 and $80M in 2028 are achieved through milestone or early product monetization"]
ALLO Risk & Opportunity Analysis
Key Investment Risks
- Heavy annual cash burn and prospective equity dilution — Operating cash burn of -$149.63M in 2025 will exhaust current liquid assets ($257.75M) by late 2027, forcing capital raises or dilutive secondary equity offerings.
- Persistent insider selling activity — 15 insider sell transactions with 0 open-market buys over the past 12 months signal management's lack of confidence in near-term share appreciation.
- Binary clinical development and regulatory trial risks — Clinical delays, safety holds, or efficacy misses in Phase I/II trials (e.g., ALLO-501A) would severely devalue the core IP portfolio.
- Persistent technical downtrend and overhead resistance — Stock has dropped 21.2% over 30 days and sits 62.6% below its 52-week high of $4.46, creating strong technical overhead resistance at $2.12-$2.50.
Growth Opportunities & Upside Drivers
- Off-the-shelf CAR-T platform technology (ALLO-501A/UCART19) — Allogeneic T-cell therapies overcome manufacturing bottlenecks of autologous CAR-T, positioning ALLO to capture market share if approved by 2028-2029 when consensus targets $350M in annual revenue.
- Near-term liquidity runway provides ~20 months of operational runway — Current assets of $257.75M against current liabilities of $32.51M buffer immediate solvency pressure, allowing clinical progression through late 2027 without immediate distress.
- Consistent operational cost management beating quarterly estimates — ALLO has beaten analyst consensus EPS estimates for 4 consecutive quarters (Q2 2026 EPS beat by $0.0445 or 25.5%), demonstrating disciplined expenditure control.
- Strong strategic backing from industry partners — Licensing and development agreements with Pfizer, Servier, and MD Anderson offer key technical validation and collaborative expertise.
ALLO Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About ALLO (ALLO)
Is ALLO stock a good investment?
The cached TradeMates AI model rates ALLO as AVOID with an investment score of 39/100. The AI model recommends an AVOID stance on Allogene Therapeutics (ALLO). While the company's off-the-shelf CAR-T pipeline offers potential long-term optionality, annual cash burn of ~$150M creates severe dilution risk for shareholders before revenue meaningfully scales toward consensus targets in 2028-2029. This is algorithmic model output, not personal investment advice.
Does ALLO pay a dividend?
The cached stock data on this page does not show a positive dividend yield for ALLO. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does ALLO stock do?
Clinical-stage immuno-oncology biotechnology firm focused on allogeneic (off-the-shelf) CAR T-cell therapies (UCART19, ALLO-501, ALLO-501A). Currently pre-revenue ($0 in 2025) and dependent on capital markets and strategic partners (Pfizer, Servier, Cellectis).
What is ALLO stock's price target?
This cached page does not contain a precise model fair value for ALLO.
Is ALLO stock a buy?
The TradeMates model verdict for ALLO is AVOID with an investment score of 39/100. Treat this as a model signal to review, not a personal buy recommendation.
Is ALLO a good dividend stock?
ALLO is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.